Sana Biotechnology presented preclinical data for SG293, an in vivo CAR T cell therapy that targets CD8+ T cells to generate CD19-directed CAR T cells, showing potent and dose-dependent CAR T cell generation and deep B cell depletion in non-human primates without lymphodepleting chemotherapy. The therapy demonstrated high specificity with minimal off-target effects and manageable side effects, supporting its potential for treating blood cancers like non-Hodgkin lymphoma and autoimmune diseases. Sana plans to start clinical trials for SG293 later this year and advance SG227, targeting multiple myeloma, by mid-2027. This approach could offer off-the-shelf CAR T treatments with improved safety and durability.
Sana Biotechnology sold about 21.6 million shares through its at-the-market (ATM) facility, raising approximately $69 million in net proceeds. This capital raise, combined with a separate $25 million investment from Mayo Clinic, totals around $94 mil...
Sana Biotechnology announced progress in its cell therapy programs, including a strategic collaboration with Mayo Clinic to develop SC451 for type 1 diabetes, aiming for a Phase 1 trial later this year. Positive 14-month clinical results were reporte...
